Immunome launches public offering of common stock; pipeline update with Phase 3 data H2 2025

Immunome Inc.

Underwritten public offering of common stock commenced; size not disclosed.
Preliminary cash, equivalents and marketable securities $217.3M as of Dec 31, 2024.
Varegacestat Phase 3 desmoid tumor trial fully enrolled; topline data expected H2 2025.
IM-1021 (ROR1 ADC) IND cleared Dec 2024; Phase 1 starts Q1 2025 at 2 mg/kg starting dose.
IM-3050 (FAP RLT) IND submission expected Q1 2025; three ADCs in IND-enabling manufacturing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.